Suman Mutation and overexpression of p53 occurs in 20-40% of breast cancers and has been shown to be an independent prognostic indicator. Recently we have demonstrated prostate-specific antigen (PSA) expression in breast tumours to be suggestive of favourable prognosis, but quantitative relationships between PSA and p53. and between these and other prognostic factors in breast cancer, have not been investigated. Time-resolved immunofluorometric procedures were used to quantify both p53 protein and PSA in 200 breast tumour extracts, which were also assayed for oestrogen (ER) and progesterone receptors (PGR), epidermal growvth factor receptors (EGFR). cathepsin D and HER-2 neu, and characterised for S-phase fraction and DNA ploidy. Weak Spearman correlations were found between p53 and ER (r = -0.18, P = 0.010), PGR (r = -0.15. P = 0.0385) and S-phase fraction (r = 0.17. P = 0.016). while PSA was correlated only with PGR (r = 0.16. P = 0.025). Wilcoxon rank sum analysis revealed that levels of ER (P = 0.0001), PGR (P = 0.0001).
Numerous biochemical and cytological features of breast cancer have been proposed to have prognostic values (Elledge et al.. 1992 : Schwartz et al., 1993 . Among these, genetic alteration of the p53 tumour-suppressor gene has been reported in hereditary breast cancer syndromes (Frebourg et al.. 1992; Sidransky et al., 1992; Glebov et al., 1994) . in 20-50% of sporadic breast carcinomas (Andersen et al., 1993; Marchetti et al., 1993; Deng et al., 1994; Faille et al.. 1994 ) and at various rates in virtually every other human malignancy (Levine et al., 1991; Hollstein et al., 1991) . The genetic lesions most often revealed are missense point mutations in evolutionarily conserved regions of the p53 gene (Mazars et al., 1992) , usually accompanied by loss of the corresponding wild-type allele (Radford et al., 1993; Singh et al., 1993) . Because the expression of mutant, stabilised p53 protein is highly correlated with p53 gene mutation (Davidoff et al., 1991; Hurlimann et al., 1994; Tsuda and Hirohashi, 1994) , demonstration of intracellular p53 protein accumulation, usually by immunohistochemical means, is an established alternative to the more laborious molecular techniques. Both p53 gene mutation and p53 protein overexpression in tumour tissue have been associated with other cinicopathological variables in breast cancer (Barbareschi et al., 1992; Poller et al., 1992; Elledge et al., 1993; Lipponen et al., 1993) and with both disease-free and overall survival (Thor et al., 1992; Allred et al., 1993; Friednrchs et al., 1993; Silvestrni et al., 1993) . although some investigations have not shown p53 to be an independent predictor of patient outcome (Ostrowski et alt, 1991 : Hanzal et alt, 1992 Isola et al., 1992) . Furthermore, the interrelationships between p53 protern expression and other prognostic factors have not been unequivocally and or quantitatively determined, since the majority of p53 investigations have been carried out with qualitative or semiquantitative procedures (Diamandis and Levesque, 1995) .
There is no shortage of potential breast cancer prognostic factors in addition to p53. Undoubtedly, the most important prognostic factor is disease stage, particularly the extent of axillary lymph node metastases (Carter et al., 1989) . Histological grade (Contesso et al., 1989) and type (O'Malley et al., 1994) of the microscopically examined tumour may also be considered in treatment decisions. Flow cytometric findings such as the percentage of cells in S-phase (Witzig et al., 1994) and DNA ploidy (Gnant et al., 1993) , as well as the related expression of the proliferation-associated markers Ki-67 (Railo et al., 1993) and PCNA (Tahan et al., 1993) , have also been reported to predict tumour behaviour. Especially evident, however, is the large number of biochemical markers whose presence, in the case of cathepsin D (CATD) (Isola et al., 1993) , epidermal growth factor receptor (EGFR) (Gasparini et al., 1994; Toi et al., 1994) , HER-2/neu (Giai et al., 1994 ), bcl-2 (Nathan et al., 1994 and p53, or absence, in the case of pS2 (Thompson et al., 1993) or of oestrogen (ER) and progesterone (PGR) receptors (Chevallier et al., 1988; Fisher et al., 1988) , may be hallmarks of aggressive tumour phenotypes. Added to this list might now be prostate-specific antigen (PSA), which has been recently shown by our group to be present in extraprostatic tissues (Yu et al., 1 994a; Levesque et al., 1995a; Yu and Diamandis, 1995) and to be suggestive of favourable prognosis when present in breast tumour tissue (Yu et al., 1994b .
In an attempt to contribute to the understanding of the relationships between p53 and other laboratory measurements on breast tumours, we have used a quantitative immunofluorometric assay for p53 in breast tumour cytosols rather than the more common immunohistochemical methods. A similar procedure was used to quantify PSA, whose 100 ILg ml-phenylmethylsulphonyl fluoride and Lg ml-' each of aprotinin and leupeptin as proteinase inhibitors. The extracts were centrifuged at 15 000 g for 30 min at 4'C, and the supernatants were collected and assayed for total protein using a bicinchoninic acid-based commercial kit (Pierce, Rockford. IL, USA) and for p53 and PSA proteins by immunofluorometric procedures described elsewhere (Hassapoglidou et al., 1993; Yu and Diamandis, 1993; Levesque et al.. 1994) . Both immunoassays employed enzymatically amplified time-resolved fluorometric detection systems (Christopoulos and Diamandis, 1992) . We expressed analyte concentration relative to the amount of total protein in the tissue extract.
Tumour extracts were considered PSA positive at concentrations equal to or exceeding 0.03 ng mg-', as discussed elsewhere 
Results
The descriptive statistics of Table I indicate that the distributions of the values of the biochemical prognostic factors and of the S-phase fraction were positively skewed. Logarithmic transformation of the p53 concentrations allowed two populations to be discerned from the histogram (Figure 1 ). Separation of these by an arbitrarily selected p53 cut-off point was made with considerations of maximising statistical power and of the detection limit of the p53 immunoassay, approximately 0.5 U g'. The choice of 5 U g-' divided specimens into 157 p53-negatives (78%) and 43 p53-positives (22%), rates which are within the range reported by others for breast cancer (Thor et al., 1992; Allred et al., 1993; Silvestrini et al., 1993) but lower than the percentage we found in ovarian cancer using the same immunological procedure (Levesque et al., 1995b) . Prostate-specific antigen is a newly demonstrated prognostic factor in breast cancer (Yu et al., 1995) and was found to be present in 26% (n = 52) of the breast cancer tumour specimens assayed in this study when a cut-off for positivity of 0.03 ng mg-was used. The distribution of logarithmically transformed PSA values is shown in for cathepsin D and 41 (21%) for HER-2/neu expression. In addition, 54% (n = 108) of the specimens were found to have an aneuploid DNA content, while 36% (n = 72) displayed an S-phase fraction greater than 6.7%.
Statistically significant, but weak, negative correlations between p53 levels and both steroid hormone receptor con- centrations were found, as was the weak positive correlation between p53 and S-phase fraction (Table II) Specimens divided into two groups on the basis of p53-positivity status using the 5 U g-cut-off were shown to differ with respect to the values of hormone receptor levels (P = 0.0001), S-phase fraction (P = 0.0001) and EGF receptor levels (P = 0.0203), as determined by the Wilcoxon rank sum analyses of Table III . This is illustrated by the much lower median oestrogen and progesterone receptor concentrations of specimens with p53 levels greater than or equal to 5 U g-' compared with p53-negative specimens (P =0.0001 for each), reflecting the negative Spearman correlations between p53 and the steroid hormone receptors. Similarly, the higher median S-phase fraction of 9.4% in the p53-positive group (P= 0.0001 Table I . Table I .
as the fraction of cells in S-phase, was significantly lower in PSA-positive tumours than in tumours with negative PSA status (P = 0.011). No other significant differences were evident in these analyses. Because the assay of HER-2/neu expression yielded only the dichotomous absence or presence of HER-2/neu protein, it was excluded from the Wilcoxon analysis of Table IV . The results of the reciprocal Wilcoxon analyses, that is of differences in p53 levels when p53 was represented as a continuous variable, between groups defined as aneuploid or diploid gave the following results: the median p53 value for diploid tumours was 1.5 U g-', compared with the median p53 for aneuploid tumours, which was 2.0 U g-' (P = 0.038). Corresponding median PSA values between diploid and aneuploid tumours were 0.019ngmg-' and 0.016ngmg-1 respectively (P=0.19). While p53 levels were also found to differ significantly between PGR-negative and PGR-positive groups (P = 0.009), and there was a trend for PSA to do so, but in the opposite direction (P = 0.06), neither p53 nor PSA differed across tumours divided on the basis of any other factor (data not shown).
Relationships between the status of p53 in the tumour specimens and the status of each additional biochemical or cytological variable were also evaluated by contingency table analysis (Table V) . Both ER-positive (P = 0.003) and PGRpositive (P<0.001) specimens tended overwhelmingly to have p53 concentrations less than 5 U g-', agreeing with the results of the Wilcoxon rank sum analysis of (845) 11 (15.5) 0 p53-negative status (P = 0.007). A positive association was also found between p53 and EGFR (P = 0.017). shown by differences between the p53-positive proportions of EGFRpositive specimens (34%) vs EGFR-negative specimens (17.7%). When the absence or presence of the categorical variable HER-2, neu protein expression was related to positivity status for p53 protein, a positive association (P=0.008) was found which had escaped detection by the Wilcoxon procedure using continuously distributed p53 values. Associations were not found between p53 and cathepsin D or PSA at the 5 U g'-cut-off point or at any other cut-off point tested in contingency tables (data not shown). The tendency of breast tumour specimens to be coclassified as positive for both PSA and PGR (P = 0.010) again indicated the strong association between these variables (Table VI) . Also significant was the association between Sphase fraction and PSA, such that PSA-positive specimens were less likely to have S-phase percentages considered signs of poor prognosis (P = 0.012). The finding of a trend relating ER status to that of PSA in the contingency table analysis (P = 0.061) but not in the Wilcoxon rank sum or correlation procedures exemplified the weaker association between PSA status and this steroid hormone receptor. Whether or not specimens were PSA positive provided no significant information as to their status of cathepsin D, EGFR or HER-2/neu expression, or of their genome copy number, although there was a trend for PSA-positive tumour to be diploid (P = 0. 10).
The p53 tumour-suppressor protein is a nuclear transcription factor shown to regulate the expression of genes mediating cell cycle arrest (Kuerbitz et al., 1992) and apoptosis (Lowe et al., 1993) (Vojtesek and Lane. 1993; Negrini et al.. 1994) . it is not surprising that p53 mutation, and hence p53 protein accumulation in tumour cells, would correlate with other markers of highly proliferative, aggressive cancers. In fact, other workers have found p53 alterations to be associated with late stage (Thor et al., 1992; Andersen et al.. 1993; Stenmark-Askmalm et al., 1994) , high grade (Thor et al., 1992; Silvestrini et al., 1993) , comedo, medullary or ductal histological types (Marchetti et al., 1993; O'Malley et al., 1994) , negative steroid receptor status (Horak et al., 1991; Isola et al., 1992; Poller et al., 1992) , expression of cathepsin D (Domagala et al., 1993) , EGFR (Barbareschi et al., 1992; Gasparini et al., 1994) or HER-2/neu (Isola et al., 1992; Poller et al., 1992; Andersen et al., 1993) , elevated S-phase fraction (Lipponen et al., 1993; Meyer and He, 1994) and aneuploid DNA content (Isola et al., 1992; StenmarkAskmalm et al., 1994) . In the vast majority of these studies, immunohistochemical approaches to detect p53 protein, or more rarely single-strand conformation polymorphism (SSCP) analysis coupled with direct sequencing, were used. In contrast to these studies, we have used an immunological assay to measure p53 concentration in breast tumour extracts.
Application of our p53 immunoassay, as previously described (Levesque et al., 1994) , to the 200 breast tumour extracts yielded a p53-positivity rate of 22% (43/200). Selection of the cut-off point at S U g-' was based on the frequency distribution of p53 values (Figure 1 ) in the study sample and the results of p53 quantification in normal breast tissue showing the 95th percentile to be less than 2 U g-' (data not shown). The receiver operator characteristic (ROC) procedure would have been inappropriate for cut-off point selection since a gold standard for breast cancer prognostication does not exist. Tumour specimens were thus classified into p53-negative and p53-positive groups in this way. Criteria for determining the status for each of the other markers, including PSA, are described above.
Consistent with our previous study of over 950 (Table V) .
Associations between the concentrations of p53 protein and the expression of other biochemical prognostic markers were also revealed. EGFR levels were found to be increased in p53-positive breast cancers, shown most clearly when both p53 and EGFR are represented as dichotomous variables (Table V) (Isola et al., 1993) , although the two markers have been found to be inversely related in another report (Domagala et al., 1993) . It is implicit from this latter report, however, that the association between p53 and cathepsin D may be obscured by the particular combination of histological types included for study, resulting primarily from the large differences in p53-positivity rates between ductal and lobular carcinomas. Because information regarding the histological types of the breast tumours studied were not available, we were unable to consider this issue. Finally, our findings that p53 and PSA were not significantly associated in any of the statistical analyses performed are concordant with our previous results (Levesque et al., 1994) . In this study, we have shown that PSA is strongly associated with low S-phase fraction and is found more frequently in diploid tumours (Table VI) 
